World-Class Biopharmaceutical Training for Academia and Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

World-Class Biopharmaceutical Training for Academia and Industry

The driving motivation behind Ireland's National Institute for Bioprocessing Research and Training (NIBRT) is to help the development of the biopharmaceutical, by developing comprehensive research and training programs for both academic students and industry professionals. By ensuring the creation and sustainability of the biopharmaceutical workforce with superior skills and competencies, the promise of more effective biotherapeutic innovations addressing the world's most challenging diseases is becoming a reality.

NIBRT provides a “one stop shop” for thousands of trainees worldwide, and offers a dynamic catalogue of course content from which unique training solutions are built for clients. NIBRT delivers holistic training programs in a realistic GMP-simulated, fully operational manufacturing environment and cutting-edge analytical laboratory suite. All training programmes can be customized to meet a client’s particular requirements.

NIBRT Key Features:

  • Purpose-built, multifunctional facility replicating the most modern industrial bioprocessing environment
  • Pilot plant consisting of extensive upstream, downstream and fill-finish facilities
  • A complete bioanalytical laboratory for hands-on scientific training of 'fit-for-purpose' biopharmaceutical analysis, including protein and peptide characterization
  • Also offer extensive course content on existing and upcoming U.S. and European drug regulations.

Get the most comprehensive overviews of the concepts, strategies and techniques – on all aspects of bioprocessing. Book your course today.

info@nibrt.ie

http://www.nibrt.ie/cat_training_schedule.jsp

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here